A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.
NeurologyLive® Friday 5 — May 17, 2024
Episode 114: AMX0035, Phase 3 PHOENIX Study, and Amylyx's Future Drug Development
Rozanolixizumab Shows No Clinical Impact on CIDP in Long-Term Phase 2 Study
Special Episode: FDA Approves HDAC Inhibitor Givinostat for Duchenne Muscular Dystrophy
Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study
This Week on NeurologyLive® — May 13 2024